Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …

Abstract Purpose of Review Approximately 10% of the adults with hypertension fail to
achieve the recommended blood pressure treatment targets on 3 antihypertensive …

Although reports vary, the prevalence of true resistant hypertension and apparent treatment-
resistant hypertension (aTRH) has been reported to be 10.3% and 14.7%, respectively. As …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

BACKGROUND: AngII (angiotensin II)-dependent hypertension causes comparable
elevations of blood pressure (BP), aldosterone levels, and renal ENaC (epithelial Na+ …

A clinical condition may be missed due to its higher-than-recognized prevalence or
inadequate diagnostic screening. Both factors apply to primary aldosteronism, which is …

Systemic hypertension (HTN) is the hallmark of cardiovascular disease and the forerunner of
heart failure. These associations have been established over decades of research on …

Resistant hypertension (RHT) is typically defined as blood pressure that remains above
guideline‐directed targets despite the use of three anti‐hypertensives, usually including a …

National Heart Center/Saudi Heart Association 2023 Guidelines on the Management of
Hypertension - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …